ARA-290 (cibinetide): what the small nerve-repair trials found

ARA-290 is one of the few peptides in circulation that has been through proper placebo-controlled trials in patients. The best of them, a 64-person phase 2b trial in sarcoidosis, found that one dose regrew small nerve fibres in the cornea over 28 days; pain fell in every group, placebo included, and the drug’s extra effect on pain wasn't statistically significant [7]. That's a real signal on nerve structure and a weak one on symptoms.

What it is

ARA-290, also called cibinetide, is an 11-amino-acid peptide built to copy one small surface of erythropoietin (EPO), the kidney hormone that tells bone marrow to make red blood cells. The idea started from an observation in the early 2000s: EPO also seemed to protect nerves, heart and kidney tissue from injury, and its developers argued that this protective effect ran through a different receptor from the one that drives red-cell production. They proposed a pairing of the EPO receptor with a second protein, CD131 (the “beta-common” receptor), and later called it the innate repair receptor [1].

In 2008 the same team showed that a short peptide mimicking the outward-facing side of one EPO helix protected tissue in rodent models of stroke, diabetic eye damage, nerve trauma and kidney injury, without raising red-cell counts in cells or animals [2]. That last point matters. EPO-type drugs can thicken the blood, and a tissue-protective fragment that avoids this would be safer to test in people.

One caveat on the mechanism. An independent Australian group tested whether the two receptors actually bind each other, with or without EPO or ARA-290 present, and found that their outer portions didn't specifically associate in the lab [3]. The “innate repair receptor” is still the developers' model, and it's contested.

What the animal work suggests

Most of the preclinical case rests on rodents. In rats with a surgically injured sciatic nerve, five injections over the first ten days reduced pain-like responses to touch and cold for up to 20 weeks, and the spinal cord's immune cells (microglia) stayed calmer than in untreated rats [4]. It's an encouraging model result, but a rat recovering from a surgical cut to one nerve is a long way from a person with years of sarcoidosis-related nerve damage, which is why the human trials are the part to focus on.

The human evidence

Human testing has been narrow: small nerve-fibre damage in sarcoidosis and type 2 diabetes, plus a couple of side studies. The same company-linked team designed or co-authored nearly all of it.

Sarcoidosis pilot, 2012

Sarcoidosis is an inflammatory disease that often damages the smallest nerve fibres, causing burning pain and fatigue. In a double-blind pilot, 22 patients received intravenous ARA-290 (2 mg three times a week, n = 12) or placebo (n = 10) for four weeks [5]. A small-fibre neuropathy symptom checklist improved more on the drug (a fall of 11.5 points versus 2.9, p less than 0.05). Scores on the Brief Pain Inventory and a fatigue scale improved in both groups by similar amounts [5]. So the headline pain measure didn't separate from placebo.

Type 2 diabetes, 2014–15

In a phase 2 trial, people with type 2 diabetes and painful neuropathy injected 4 mg of ARA-290 or placebo under the skin daily for 28 days and were followed for another 28 days [6]. The ARA-290 group had better HbA1c and blood lipids over the 56 days, and better scores on the PainDetect neuropathy questionnaire. Corneal nerve fibre density rose in participants who started with the most nerve loss [6]. The trial was small, and 28 days is short for judging blood-sugar control, so treat this as a lead worth chasing.

Sarcoidosis phase 2b, 2017

This is the trial to know.

Corneal nerve fibre area, the primary endpoint, is measured by imaging the thin nerves in the front of the eye, which track small-fibre damage elsewhere in the body. Only the middle dose worked, and the highest dose didn't, which is an odd dose–response [7]. Skin biopsies showed more regenerating nerve fibres at 4 mg (p = 0.035), and nerve-area gains correlated with better six-minute walk distance. For people with moderate to severe pain, the placebo-corrected drop in pain at 4 mg was described as clinically meaningful but had p = 0.157 [7]. Several authors were officers of, or consultants to, the developer, Araim Pharmaceuticals.

Why the trials measure eye nerves

If you're wondering why a pain drug is judged by pictures of the eye, it's a practical choice. Small-fibre neuropathy is normally confirmed with a skin biopsy that counts nerve endings, which is invasive and hard to repeat every few weeks. Corneal confocal microscopy photographs the fine nerves in the clear front of the eye in a few minutes, and the same team (again including the developer's staff) has argued that the size and area of those fibres track how severe the neuropathy is and pick up regrowth after treatment [11].

That makes corneal nerve area a sensible early signal. It is still a surrogate endpoint, a stand-in measured because the thing patients care about (less burning pain, more energy, walking further) is noisier and slower to shift. Drug development is full of treatments that moved a surrogate and then failed on symptoms or survival. The 2017 trial's correlation between nerve-area gains and walking distance is encouraging [7], but correlations inside a 64-person trial aren't proof that one causes the other. A phase 3 trial with pain and function as the main outcome would settle it, and none has been published.

It's also worth being clear about what the diabetes result does and doesn't show. Better HbA1c after four weeks of injections [6] would be a big deal if it held up, since HbA1c moves slowly and reflects roughly three months of blood sugar. With a small trial and no replication, it's a finding to test, not one to act on.

Other human studies

A small open-label phase 2 study in Belfast gave 4 mg daily for 12 weeks to nine people with diabetic macular oedema (eight finished). Vision, retinal thickness and retinal sensitivity didn't improve on average, though some participants improved on individual measures and no antibodies against the drug appeared [8]. In 36 healthy volunteers, a single 2 mg dose produced mixed effects on how the brain processed emotional faces, with no effect on mood, and the authors said the results didn't clearly support an antidepressant profile [9].

Safety and side effects

None of the published trials reported serious safety concerns. The sarcoidosis pilot found nothing of note on clinical or laboratory checks [5], the diabetes trial identified “no potential safety issues” [6], and the macular oedema study saw no serious adverse reactions and no anti-drug antibodies over 12 weeks [8]. That's reassuring as far as it goes, but it rests on fewer than 150 treated people, mostly for four weeks. Nobody knows what months or years of use would do, and there are no drug-interaction studies.

Legal and regulatory status

Cibinetide has never been approved as a medicine by any regulator, including in the UK and US, and it stopped after phase 2; we found no phase 3 trial. Anti-doping scientists at the German Sport University Cologne describe ARA-290 as a peptide prohibited in sport and have worked out how to detect its breakdown products in blood [10]. Athletes subject to testing should assume it's banned.

What we still don’t know

• Whether regrown corneal nerve fibres translate into less pain or better function once trials are large enough to tell.
• Why 4 mg worked in the phase 2b trial while 8 mg didn't.
• Whether the effect lasts after treatment stops, and what repeated courses do.
• Whether it works through the proposed repair receptor at all, given the independent lab data against a direct receptor pairing [3].
• Whether any group outside the developer's network can reproduce the results.

Educational content only — not medical advice. Many peptides discussed on HPR are not approved for human use. Talk to a qualified clinician before making any decision about your health.

Free live webinar · Thursday 1 October · 7pm UK time

Join the next webinar: Introduction to Peptides

with Mitch O’Callaghan, ISSCA Peptide Therapist · Founder, Proper Protocols

Save my free placeHPR×Proper Protocols